Brandon is Chief Artificial Intelligence Officer at Valo where he leads data and modeling research and development.
Brandon previously co-founded Numerate in 2007 and served as CTO from 2013 until its acquisition by Valo Health in 2019. Prior to the acquisition, he helped to make Numerate the world-leading AI drug design company through the development of its D4 platform.
He is an industry leader in the application of AI in life science. He has authored scientific publications in machine learning, chemistry, biology, physics, and astronomy and has 18 years of experience in AI, mathematical modeling, and large-scale cloud and distributed computing. Brandon is also a co-founder of the Alliance for AI in Healthcare and currently serves on the executive leadership.
Brandon holds a B.S. in Physics from the University of Washington, Seattle, and a Ph.D. in Computational Physics from the University of California, Santa Cruz.
Professor of Medicine (Immunology), Strasbourg University
Seiamak Bahram, MD, PhD, is Professor of Medicine (Immunology) at the Strasbourg University School of Medicine and Teaching Hospitals, Strasbourg, France. He is a senior member of the “Institut universitaire de France” (IUF). He graduated from the Strasbourg School of Medicine upon which he did his PhD research at the Dana-Farber Cancer Institute – Harvard Medical School (Boston, USA). Upon returning to Europe, he accepted a position as a member of the Basel Institute for Immunology (Roche, Basel, Switzerland). He then moved back to Strasbourg, first as an Associate and then full Professor at the school of Medicine. Additionally, he is the head of the Department of Immunology at Strasbourg University Hospitals.
His research aims at understanding the genetic basis of the immune response in man with emphasis on non-conventional histocompatibility genes. He is internationally known for the identification of several immune response genes, notably the MHC class I chain-related MIC genes. He is the director of INSERM Unit 1109 and the Laboratory of Excellence (LabEx) Transplantex.
Vice President, Global Head, Health Economics and Outcomes, Abbvie
Christopher Boone, PhD has a career-long history as a dynamic, innovative thought leader and a public voice on the power of real-world evidence, health informatics, and big data analytics and its ability to radically transform the global health care system into a learning health system.
Chris currently serves as the Vice President, Global Head of Health Economics and Outcomes Research at Abbvie. He is also an adjunct assistant professor of health administration at the New York University’s Robert F. Wagner Graduate School of Public Service, an active board member of several influential organizations, and a co-founder of a few start-up companies. Most recently, he served as the vice president and head of global medical epidemiology and big data analysis at Pfizer.
Chris has been recognized as a 2019 Top 100 Innovator in Data & Analytics, a 2018 Emerging Pharma Leader by Pharmaceutical Executive, and a 2017 Top 40 Under 40 Leader in Minority Health by the National Minority Quality Forum (NMQF).
Boone holds, or has held, appointments to some of the most influential national committees focused on health data and patient centricity, including the Board of Directors for the Stewards of Change Institute, the Executive Board of Directors for the Patient Advocate Foundation, the Executive Board of Directors for the National Patient Advocate Foundation, the Board of Directors for SHARE for Cures, the Robert Wood Johnson Foundation’s Data Across Sectors for Health (DASH) Initiative, the Interoperability Committee for the National Quality Forum, the National Committee on Vital and Health Statistics (NCVHS) Working Group on HHS Data Access and Use, the Health IT Policy Committee (federal advisory committee), and the advisory group for the American Society of Clinical Oncologists’ (ASCO) CancerLinQ initiative.
Chris earned a B.S. from the University of Tulsa, a M.H.A. from the University of Texas at Arlington, a Ph.D. from the University of Texas at Dallas, and two executive certificates from the Harvard Kennedy School. He is a Fellow of the American College of Health Executives and a Fellow of the Healthcare Information Management & Systems Society.
Chief Technology Officer, Genuity Science; President and Founding Director, Genuity AI Research Institute
Tom Chittenden is Chief Technology Officer and Founding Director of the Genuity Science Advanced Artificial Intelligence Research Laboratory. Tom is responsible for development and execution of our global AI/ML R&D strategy. This R&D initiative includes development of advance deep learning, statistical machine learning, and probabilistic programming analytics aimed at furthering scientific understanding of human disease initiation and progression, knowledge that can be directly applied in innovative products for better care and medicine in a range of disease areas.
The principal focus of the work of Tom and his team is the development and application of integrated systems biology models to investigate evolutionary factors of human disease. The broad objective is to understand how genetic variation and somatic mutation regulate aberrant gene activity and subsequent disease biology. To this end, Tom spent a year as a Visiting Research Scientist in the Department of Statistics at the University of Oxford, where he formulated a general strategy for constructing machine learning models by integrating a priori biological knowledge with multiple types of high-throughput genomic and phenotype data.
Tom’s work has been published in top-tier scientific journals, including featured articles in Nature and Science. In 2019, he was named among the top 100 A.I. Leaders in Drug Discovery and Advanced Healthcare by Deep Knowledge Analytics and winner of the 2021 Artificial Intelligence Excellence Awards by the Business Intelligence Group. He is regarded as one of the world’s leading authorities on A.I. and causal statistical machine learning in precision medicine.
Tom is an Accredited Professional Statistician™ with the American Statistical Association. In addition to his position at Genuity Science, he holds academic faculty appointments at Boston Children’s Hospital and the Harvard Medical School (HMS), where he lectures on biostatistics and mathematical biology. From 2016 to 2018, Tom held a Visiting Lecturer appointment in the Department of Biological Engineering at the Massachusetts Institute of Technology. He currently serves as a Senior Consultant for the HMS Research Computing Group. He is a Senior Fellow and Chief Statistical Sciences Advisor for the Global Strategic Initiatives and Planning Committee of the International Society for Philosophical Enquiry.
Tom holds a PhD in Molecular Cell Biology and Biotechnology from Virginia Tech and a DPhil in Computational Statistics from the University of Oxford. His multidisciplinary postdoctoral training includes experimental investigations in Molecular and Cellular Cardiology from the Dartmouth Medical School and Integrative Functional Genomics, Biostatistics, and Mathematical Biology from the Dana-Farber Cancer Institute and the Harvard School of Public Health.
Robert Rock Belliveau Endowed Professor, Pathology & Immunology; Professor of Medicine, Washington University School of Medicine
Dr. Marco Colonna was born in Parma, Italy, received his medical degree and specialization in internal medicine at Parma University (Parma, Italy) and completed his postdoctoral training at Harvard Medical School (Cambridge, Massachusetts, USA). He became a scientific member of the Basel Institute for Immunology (Basel, Switzerland). Since 2001 he has been a Professor of Pathology & Immunology at Washington University School of Medicine in St. Louis, MO, USA. Since 2018 Dr. Colonna is a member of the National Academy of Science. Dr. Colonna’s research focuses on immunoreceptors. In this field his accomplishments encompass identification and characterization of the Killer cell Ig-like receptors and HLA-C polymorphisms as their inhibitory ligands, as well as the discovery of the LILR and TREM inhibitory and activating receptor families. Through analysis of the cellular distribution of these receptors, he identified plasmacytoid dendritic cells as source of IFN-/ in anti-viral responses and innate lymphoid cells that produce IL-22 in mucosae. His current areas of research include: 1) Innate lymphoid cells in mucosal immunity. 2) Plasmacytoid dendritic cells in host defense and autoimmunity. 3) TREM2 and innate immunoreceptors in Alzheimer’s disease.
Vern is the Chief Partnership Officer and supports Cyclica’s growth by scaling Cyclica’s partnership efforts and global presence. Prior to joining Cyclica Vern served in multiple senior leadership roles with over 20+ years of experience in discovery and late stage development, working with the internationally recognized pharmaceutical company, GlaxoSmithKline (GSK). In his most recent position as Head of Digital, Data and Analytics, Vern lead a team tasked with realising competitive advantage and value through digital, data and analytics, associated with a 3,000 employee global R&D Discovery and preclinical organisation. Prior to that, Vern held the role of Head of Emerging Platforms, where he led a team tasked with discovering and incubating new external platforms for GSK R&D, and Head of Platform Technology and Science at GSK R&D, Asia in Shanghai. In these roles, Vern oversaw the development of novel transformational platforms in areas of AI and deep learning, miniaturised biology with the application of scientific and computational power to the R&D process. Vern has global experience having worked in Italy, China, the UK, and the United States. Vern received his PhD in Analytical Chemistry from the University of Hertfordshire, UK.
Brian Donnelly is the Worldwide Leader of Diagnostics & Genomics at Amazon, where he oversees business strategy and business development efforts to accelerate genomic discoveries through adoption of cloud technology and machine learning across the healthcare, life sciences, and agriculture verticals. Brian has held a variety of global operational leadership roles in leading genomics and life sciences organizations including Illumina, Sequenom, Codex DNA, Allergan, and GlaxoSmithKline. Brian served as Chief Commercial Officer at Codex DNA leading commercialization of the world’s first synthetic gene printer. At Illumina, Donnelly held a variety of global leadership roles including General Manager of the Customer Solutions + Experience organization, leading the Global Commercial Strategy organization, and leading the Global Clinical Marketing team. Brian is passionate about the intersection of -omics and wellness and a champion for genomic research and the rare disease community. He holds a JD and MBA from Rutgers University and a Bachelor’s degree in Business Administration from Elon University.
Steve has over 25 years’ experience building world-class teams, products and companies including as Global Director of Research Informatics for Astra. He has raised venture funding in the UK, EU and USA to develop and market highly innovative and commercially successful products in the life science, healthcare and food industries.
Steve was Global Director of Research Informatics for Astra. He has developed world-leading genomics, digital health, smart IoT and informatics technologies including several patented inventions. He was heavily involved in developing some of the core informatics systems used by major genomics companies during the initial Human Genome project and has worked extensively with major pharma companies on over 25 drug discovery and safety projects.
Steve specialises in AI enabled drug discovery and precision medicine, large-scale genomics, semantic data integration and complex data analytics for life science, healthcare and clinical decision support. Steve has served as an Advisory Council member for Breast Cancer Now and a Steering Committee member of the UKCRC Tissue Coordination Centre.
Assistant Director, Research in Omics, OptumLabs – R&D, United Health Group
Taryn Hall, MPH, PhD is an Assistant Director of Research in Omics at OptumLabs, the Research and Development arm of UnitedHealth Group, a large healthcare organization that also includes a payor (UnitedHealthcare) and clinical services organization (Optum). In her role, Taryn works to create innovation within the field of healthcare by translating advances in genomics into population health management and the clinic while balancing many stakeholder points of view. Taryn is an interdisciplinary scientist, trained in genetic epidemiology, statistical genetics, bioethics, and policy, and earned her PhD in Public Health Genetics from the University of Washington. She is also a former National Library of Medicine Fellow in Bioinformatics and was formerly the Diabetes Epidemiologist for the State of Montana.